home > news > detailed info

4G Clinical Ranks No. 28 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies

4G Clinical

WELLESLEY, MA, MARCH 15, 2022 – Inc. magazine announced that 4G Clinical is ranked 28th on the third annual Inc. 5000 Regionals: Northeast list, recognizing the company’s 518% growth in a two-year span between 2018 and 2020. This prestigious ranking of the fastest-growing private companies based in Connecticut, Massachusetts, Maine, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont represents a unique look at the most successful companies within the Northeast region’s independent small businesses.

“Being recognized as one of the fastest-growing private companies in the Northeast Region is a tremendous honor—and an equally tremendous accomplishment—for 4G Clinical,” said David Kelleher, CEO, 4G Clinical. “In a year that has already seen unprecedented growth for our company, we plan to continue scaling in alignment with our goals of improving patients' lives around the globe, and enabling researchers to follow the science, wherever it may lead.”

This recognition further highlights the company’s notable growth, coming just months after the publication ranked 4G Clinical #111 on its Inc. 5000 list of the nation’s fastest-growing private companies.

The companies on the Inc. 5000 Regionals Northeast list show a remarkable rate of growth across all industries in the region. Between 2018 and 2020, these 124 private companies had an average growth rate of 208%, and, in 2020 alone, they added 5,010 jobs and nearly $2.7 billion to the Northeast region’s economy.

Complete results of the Inc. 5000 Regionals Northeast, including company profiles and a sortable interactive database can be found at beginning March 15, 2022.

“This year’s Inc. 5000 Regional winners represent one of the most exceptional and exciting lists of America’s off-the-charts growth companies. They’re disruptors and job creators, and all delivered an outsize impact on the economy. Remember their names and follow their lead. These are the companies you’ll be hearing about for years to come,” says Scott Omelianuk, editor-in-chief of Inc.
phone 781-694-1400
email 370 Washington Street Wellesley, MA 02481
Print this page
Send to a friend
News and Press Releases

Ubiquigent Obtains Exclusive License for UbiSite Technology to Strengthen its Specialist Drug Discovery Services

Dundee, UK, 31 October 2022: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as new therapeutics for areas of high unmet medical need, has signed an exclusive license with the University of Southern Denmark for its UbiSite® technology. UbiSite will form a new component in Ubiquigent’s DUB and ubiquitin-proteasome system (UPS) focused drug discovery platform, providing a fully supported ubiquitomics service to facilitate target identification, target validation, and compound mechanism of action.
More info >>

White Papers

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement